Volasertib, Boehringer Ingelheim Corporation´s Investigational Treatment Of Acute Myeloid Leukaemia, Is Granted "Orphan Drug Designation" In The EU And The U.S.
4/17/2014 9:42:55 AM
INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the US and UK only. Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) and the European Commission have granted volasertib* ‘orphan drug designation’ for the treatment of patients with acute myeloid leukaemia (AML).
Help employers find you! Check out all the jobs and post your resume.
comments powered by